BRAF and melanoma: Patients with an MPR did not receive any adjuvant treatment, and patients who had a pPR or pNR received adjuvant dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) for 46 weeks if they had BRAF-mutated melanoma or an additional 11 cycles of adjuvant nivolumab (480 mg every 4 weeks) if they had BRAF wild-type melanoma.